Patent Grant
10660880
The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist. The present invention also provides a kit containing different units of medication of a selective S1P1 receptor agonist for administration according to the invention, whereby one or more units of a dose strength below the target dose of said selective S1P1 receptor agonist are provided for the initial treatment phase, and subsequent units of medication of higher dose strengths up to the target dose of said selective S1P1 receptor agonist are provided.
The present invention provides a dosing regimen for a selective S1P1 receptor agonist, by which adverse effects are minimized in subjects/patients during the initial treatment phase, or upon re-initiation of dosing after drug discontinuation.
Selective S1P1 receptor agonists are compounds which preferentially activate the human S1P1 receptor sub-type from among the S1P1, S1P2, S1P3, S1P4, and S1P5 family members of sphingosine-1-phosphate-sensitive human G-protein coupled receptors. S1P receptor agonists decrease the number of circulating lymphocytes in peripheral blood in humans or animals after e.g. oral administration, therefore they have therapeutic potential in a variety of diseases associated with a dysregulated immune system. For example, the non-selective S1P receptor agonist FTY720 has been found to reduce the rate of clinical relapses in multiple sclerosis patients (Kappos L et al., N Engl J Med. 2006 Sep. 14, 355(11): 1124-40).
However, SIP receptor agonists have been described to reduce heart rate in rodent animal models, an effect that has been attributed to the activation of the S1P3 receptor in the sinoatrial nodal tissue of the heart, which increases the IK,Ach inward rectifier current, and slows the sinoatrial pacemaker (Hale J J et al., Bioorg Med Chem Left. 2004, 14(13): 3501-5; Bunemann Metal., J Physiol 1995, 489: 701-707; Guo J et al., Pflugers Arch 1999, 438: 642-648; Ochi R et al., Cardiovasc Res 2006, 70: 88-96). Moreover, the non-selective S1P receptor agonist FTY720 reduces heart rate in humans (Koyrakh L et al., Am J Transplant 2005, 5: 529-536), and the literature suggests that S1P1 selective compounds would have diminished effects on heart rate in humans, compared to non-selective S1P receptor agonists (Himmel H M et al., Mol Pharmacol 2000, 58: 449-454; Peters S L, Alewijnse A E, Curr Opin Pharmacol. 2007, 7(2): 186-92; Fujishiro J et al., Transplantation 2006, 82(6): 804-12; Sanna M G et al., J Biol Chem. 2004, 279(14): 13839-48).
The compound (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one (hereinafter also referred to as “Compound 1”; the preparation of Compound 1 and the medicinal use thereof, is described in the published PCT application WO 2005/054215) is a selective S1P1 receptor agonist, and repeated daily oral dosing of 5 mg or more to humans results in a consistent, sustained, and dose-dependent reduction in the number of peripheral blood lymphocytes. It has been surprisingly found, however, that the selective S1P1 receptor agonist Compound 1 transiently reduces heart rate in humans, with maximal effects 1-3 hours after administration. In some individuals this is accompanied by similarly transient increases in the PR interval in the electrocardiogram (ECG), and an associated irregular heart rhythm (so-called Wenckebach rhythm). Occasional fatigue or dizziness also occur in the post-dose period. These acute effects of Compound 1 on heart rate and rhythm and fatigue/dizziness are milder at 10 mg than at 20 mg. All of these effects wane with repeated dosing. Thus, after 2 to 4 days of daily oral doses of 5 to 20 mg, an acute heart rate reduction, compared to the pre-dose value, is no longer observed upon administration of Compound 1. Similarly, with repeated daily oral dosing of 5 to 20 mg of Compound 1, transient increases in the PR interval of the ECG relative to pre-dose values are not observed, nor are fatigue or dizziness reported. The acute effects on heart rate, atrioventricular conduction, or fatigue and dizziness, although not seriously adverse, are undesirable, and methods to minimize these effects would be valuable for maximizing the tolerability and safety of Compound 1, and other selective S1P1 receptor agonists, and minimizing associated monitoring requirements, in the early phase of dosing initiation, or, after a drug interruption, at re-initiation of drug therapy.
The subject matter of the present invention therefore provides a dosing regimen for selective S1P1 receptor agonists, such as and especially Compound 1, which minimizes the incidence or severity of the stated adverse effects. The dosing regimen of the present invention provides that a selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist. The dosing regimen of the present invention has the advantage that a desensitization of the heart can be induced and sustained at a dose below the target dose with less pronounced acute heart rate reduction when compared to giving the target dose without such a dosing regimen. The dosing regimen of the present invention therefore results in an improved tolerability by minimizing the adverse effects in subjects/patients during the first days of dosing of a selective S1P1 receptor agonist, or upon re-initiation of dosing after drug discontinuation.
The choice of the dosing regimen (i.e., the magnitude of the dose and the dosing frequency) during the initial treatment period can be arrived at empirically, by comparing the magnitude of the acute heart rate reduction between initial doses given. The dosing frequency should be convenient for the patient, it should be longer than the duration of the acute heart rate reduction, and it should be shorter than the time required for the heart to recover from desensitization. The thus empirically chosen dosing frequency, will reflect the relative rate constants of several independent processes: the rate constant for the concentration of the S1P1 receptor agonist in the body to exceed a concentration threshold associated with desensitization; the rate constant for desensitization of the heart; and the rate constant for the recovery from desensitization of the heart. The latter two rate constants (for desensitization of the heart, and for recovery from desensitization) are intrinsic properties of the underlying biological processes that give rise to these phenomena. The first rate constant (for exceeding the concentration threshold) is determined by the pharmacokinetics of the S1P1 receptor agonist, i.e., on the rates of absorption, distribution, metabolism and excretion of the drug. In view of the above-mentioned three rate constants, the duration of a suitable dosing interval will be dose-dependent.
For example, Compound 1, when given as a 20-mg once-daily dose by the oral route, results in an acute heart rate reduction on Day 1, and when the second 20-mg dose is administered 24 hours later, no acute heart rate reduction is observed. Desensitization has been sustained over this 24-hour dosing interval. Yet, when a second 20-mg dose is administered 7 days after the first dose, it results in an acute heart rate reduction of similar magnitude as on Day 1. Desensitization has not been sustained over this 7-day dosing interval of the 20-mg dose. This example illustrates that a suitable dosing interval is necessary to sustain desensitization of the heart.
i) In particular, the present invention relates to a selective SIP, receptor agonist for use as a medicament, whereby said selective S1P1 receptor agonist is administered to a subject (especially a human subject) in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
ii) In a further embodiment, the present invention relates to the selective S1P1 receptor agonist for use as a medicament according to embodiment i), whereby the initial dose below the target dose is between 2- to 5-fold lower than the target dose.
iii) In a further embodiment, the present invention relates to the selective S1P1 receptor agonist for use as a medicament according to embodiment i), whereby the initial dose below the target dose is between 5- to 16-fold lower than the target dose.
iv) In a further embodiment, the present invention relates to the selective S1P1 receptor agonist for use as a medicament according to any one of embodiments i) to iii), whereby a dose below the target dose is administered to the subject during the initial 2 to 4 days of the treatment.
v) In a further embodiment, the present invention relates to the selective S1P1 receptor agonist for use as a medicament according to any one of embodiments i) to iv), whereby the dose below the target dose is administered at a dosing frequency of once or twice daily.
vi) In a further embodiment, the present invention relates to the selective S1P1 receptor agonist for use as a medicament according to any one of embodiments i) to v), wherein the selective S1P1 receptor agonist is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, or a pharmaceutically acceptable salt thereof.
vii) In a further embodiment, the present invention relates to the use of a selective S1P1 receptor agonist in the manufacture of a medicament, whereby said medicament is administered to a subject as specified in any one of embodiments i) to v).
viii) In a further embodiment, the present invention relates to the use according to embodiment vii), wherein the selective S1P1 receptor agonist is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, or a pharmaceutically acceptable salt thereof.
ix) The present invention also relates to a kit containing different units of medication of a selective S1P1 receptor agonist for administration according to embodiment i), whereby one or more units of a dose strength below the target dose of said selective S1P1 receptor agonist are provided for the initial treatment phase, and subsequent units of medication of higher dose strengths up to the target dose of said selective S1P1 receptor agonist are provided.
x) In a further embodiment, the present invention relates to the kit according to embodiment ix), wherein the selective S1P1 receptor agonist is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, or a pharmaceutically acceptable salt thereof.
xi) In a further embodiment, the present invention relates to the kit according to embodiment ix) or x), whereby subsequent units of medication of 2- to 5-fold higher dose strengths compared to the initial dose strength are provided.
xii) In a further embodiment, the present invention relates to the kit according to embodiment ix) or x), whereby subsequent units of medication of 5- to 16-fold higher dose strengths compared to the initial dose strength are provided.
xiii) In a further embodiment, the present invention relates to the kit according to any one of embodiments ix) to xii), whereby the dose strength units below the target dose are provided for the initial 2 to 4 days of treatment.
xiv) In a further embodiment, the present invention relates to the kit according to any one of embodiments ix) to xiii), whereby the dose strength unit(s) below the target dose is/are administered at a dosing frequency of once or twice daily.
xv) The present invention further also relates to a method for administering a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject as specified in any one of embodiments i) to v).
xvi) In a further embodiment, the present invention relates to the method according to embodiment xv), wherein the selective S1P1 receptor agonist is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, or a pharmaceutically acceptable salt thereof.
The general terms used hereinbefore and hereinafter preferably have, within this disclosure, the following meanings:
The term “desensitization of the heart” as used herein refers to the absence of an acute heart rate reduction after drug administration.
The term “acute heart rate reduction” as used herein refers to a heart rate decrease from pre-dose values of, for example, 10 or more beats per minute (bpm), that is maximal within a few hours, for example 1-3 hours, after drug administration, and thereafter the heart rate returns towards the pre-dose value.
The term “target dose” as used herein refers to the dose of a selective S1P1 receptor agonist that achieves target peripheral blood lymphocyte counts, e.g., 400-800 lymphocytes per microliter. The target dose for a given S1P1 receptor agonist may vary depending on the nature and severity of the disease to be treated.
Dose up-titration to the target dose can be achieved in one or several dose increments. For example, a suitable dosing regimen for Compound 1 can be 5 mg p.o. (once daily for 3 days; the initial treatment phase), followed by up-titration to 10 mg p.o. (once daily for 3 days), followed by up-titration to 20 mg p.o. (the target dose) given once daily indefinitely. Another example of a suitable dosing regimen for Compound 1 can be 5 mg p.o. (once daily for 3 days; the initial treatment phase), followed by up-titration to 20 mg p.o. (the target dose) given once daily indefinitely.
Selective S1P1 receptor agonists according to the present invention are compounds which preferentially activate the human S1P1 receptor sub-type from among the S1P1, S1P2, S1P3, S1P4, and S1P5 family members, especially compounds which possess a potency for activation of the S1P1 receptor over the other family members of at least 5-fold in a suitable assay. Such suitable assays to determine S1P receptor agonist activities are known in the art. In particular, S1P1 receptor agonist activity of a compound can be tested using the GTPγS assay as described for example in WO 2007/080542 for the human S1P1 receptor. The same assay can be used to determine the agonist activities of a compound regarding the other S1P family members by using CHO cells expressing recombinant human S1P2, S1P3, S1P4, and S1P5 receptors, respectively.
Preferred selective S1P1 receptor agonists according to the present invention, their preparation and medicinal use are disclosed in the published PCT applications WO 2005/054215, WO 2005/123677, WO 2006/010544, WO 2006/100635, WO 2006/100633, WO 2006/100631, WO 2006/137019, WO 2007/060626, WO 2007/086001, WO 2007/080542, WO 2008/029371, WO 2008/029370, WO 2008/029306, WO 2008/035239, WO 2008/114157, and WO 2009/024905.
The selective S1P1 receptor agonists and their pharmaceutically acceptable salts, can be used as a medicament, e.g., in the form of pharmaceutical compositions for enteral or parenteral administration, and are suitable for the prevention and/or treatment of diseases or disorders associated with an activated immune system.
The term “pharmaceutically acceptable salts” refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to “Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201-217.
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the selective S1P1 receptor agonists or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
Such diseases or disorders associated with an activated immune system which can be treated and/or prevented with selective S1P1 receptor agonists are described for example in WO 2005/054215.
Preferred diseases or disorders to be treated and/or prevented with selective S1P1 receptor agonists are selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, and uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, and dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers; and tumor metastasis.
Particularly preferred diseases or disorders to be treated and/or prevented with selective S1P1 receptor agonists are selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis. Very preferably the diseases or disorders to be treated and/or prevented with selective S1P1 receptor agonists are selected from multiple sclerosis and psoriasis.
Furthermore, selective S1P1 receptor agonists are also useful, in combination with one or several immunomodulating agents, for the prevention and/or treatment of the diseases and disorders mentioned herein. According to a preferred embodiment of the invention, said agents are selected from the group consisting of immunosuppressants, corticosteroids, nonsteroidal anti-inflammatory drugs, cytotoxic drugs, adhesion molecule inhibitors, cytokines, cytokine inhibitors, cytokine receptor antagonists, and recombinant cytokine receptors.
To date, Compound 1 has been administered to humans in three Phase 1 studies. In total, 85 subjects have been treated with Compound 1, at single doses of up to 75 mg, and at multiple doses of up to 40 mg for up to 15 days.
In the single-ascending dose (SAD) study (AC-058-101), Compound 1 was administered orally to 6 groups of 6 healthy male subjects (aged 21-47 years). Doses of 1, 3, 8, 20, 50 and 75 mg were given to sequential groups of 8 subjects (6 on active drug and 2 on placebo) in a randomized, double-blind, placebo-controlled design. The dose of 20 mg was given once in the fasted and once in the fed condition, to assess any food effects on the pharmacokinetics of Compound 1. ECGs were recorded, clinical laboratory parameters, vital signs, pulmonary function, neurological assessments (in the 75-mg dose group), plasma levels of Compound 1, and peripheral lymphocyte counts (total and subsets) were determined. All 48 randomized subjects were evaluable and no subjects withdrew or discontinued from the study. All subjects treated with Compound 1 (n=36) were included in the pharmacokinetic (PK) and pharmacodynamic (PD) analysis.
In Part A of the multiple-ascending dose (MAD) study (AC-058-102), Compound 1 was administered orally with doses of 5, 10, and 20 mg once-daily for 7 days to healthy male and female subjects (aged 22-58 years, 1:1 sex ratio) in a randomized, double-blind, placebo-controlled design. At each dose level, a group of 10 subjects were randomized to Compound 1 (8), or placebo (2). In Part A, all 30 randomized subjects completed the study and the 24 subjects who were treated with Compound 1 were included in the PK analysis.
In Part B of the MAD study, an up-titration scheme was implemented in order to reduce first-dose effects of Compound 1 on sinus node automaticity and atrioventricular- (AV-) conduction. Treatment with Compound 1 started for 4 days with 10 mg once daily, followed by 4 days with 20 mg once daily, and 7 days with 40 mg once daily. Seventeen subjects (nine females and eight males, aged 18-43 years) were randomized. Thirteen subjects received active treatment and four subjects received matching placebo. A total of 15 out of the 17 subjects completed the study as scheduled. Dosing was discontinued in two subjects on active treatment due to adverse events, in one case a moderate tooth infection and edema in the mouth, and in the other, a moderate granulocyte shift to the left in the peripheral blood smear, which was already present at baseline. The 11 subjects treated with 40-mg Compound 1 who completed the study were included in the PK analysis of Compound 1.
Table 1 shows the comparison of the mean heart rate (HR) reduction at 2.5 h post-dose vs pre-dose in the 40-mg dose group (AC-058-102, Part B) after each titration step (Day 1 for 10 mg, Day 5 for 20 mg, and Day 9 for 40 mg) vs HR reduction without up-titration on Day 1 (10 and 20 mg Part A of AC-058-102 and 50 mg of AC-058-101).
The mean HR reduction at 2.5 h post-dose vs pre-dose in the 40-mg dose group (AC-058-102, Part B) on days 2, 3, and 4 (10 mg) was 2 bpm, 1 bpm, and 1 bpm, respectively, and 4 bpm, 3 bpm, and 3 bpm on days 6, 7, and 8 (20 mg), respectively.
During Part B of the study, only one subject reported a transient AV-block first degree after administration of the first 10 mg dose of Compound 1 on Day 1, suggesting that up-titration reduces the effects of Compound 1 on both sinus node automaticity and AV-conduction. No second or third degree AV-blocks were observed during Part B of the study. No relevant effects on other ECG variables were recorded with multiple dosing in Part B.
| Number | Date | Country | Kind |
|---|---|---|---|
| PCT/IB2008/050995 | Mar 2008 | WO | international |
This application is a divisional of U.S. application Ser. No. 12/922,777, filed Sep. 15, 2010, which claims benefit under 35 U.S.C. 371 of PCT Application No. PCT/IB2009/051030, filed on Mar. 12, 2009, which claims the benefit of PCT Application No. PCT/IB2008/050995, filed on Mar. 17, 2008, the contents of each of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 6197829 | Fujii et al. | Mar 2001 | B1 |
| 6277888 | Sakai et al. | Aug 2001 | B1 |
| 6476004 | Sakai et al. | Nov 2002 | B1 |
| 6667025 | Chiba et al. | Dec 2003 | B2 |
| 6828091 | Kasibhatla | Dec 2004 | B2 |
| 7435828 | Binkert | Oct 2008 | B2 |
| 7626037 | Binkert et al. | Dec 2009 | B2 |
| 7875726 | Binkert et al. | Jan 2011 | B2 |
| 7879821 | Hauser et al. | Feb 2011 | B2 |
| 8263780 | Abele et al. | Sep 2012 | B2 |
| 8273779 | Binkert et al. | Sep 2012 | B2 |
| RE43728 | Binkert et al. | Oct 2012 | E |
| RE43833 | Binkert et al. | Nov 2012 | E |
| 8415484 | Jones et al. | Apr 2013 | B2 |
| 8492441 | Legangneux | Jul 2013 | B2 |
| 8524752 | Binkert et al. | Sep 2013 | B2 |
| 8785484 | Brossard et al. | Jul 2014 | B2 |
| RE45174 | Binkert et al. | Sep 2014 | E |
| 8879821 | Shimura | Nov 2014 | B2 |
| 20030003099 | Lake et al. | Jan 2003 | A1 |
| 20100160259 | Schmouder et al. | Jun 2010 | A1 |
| 20110039818 | Legangneux et al. | Feb 2011 | A1 |
| 20110196004 | Bonham et al. | Aug 2011 | A1 |
| 20110257133 | Schmouder et al. | Oct 2011 | A1 |
| 20120302758 | Abele et al. | Nov 2012 | A1 |
| 20130310432 | Binkert et al. | Nov 2013 | A1 |
| 20140315964 | Brossard et al. | Oct 2014 | A1 |
| 20150087720 | Kovarik et al. | Mar 2015 | A1 |
| 20150203459 | Herse et al. | Jul 2015 | A1 |
| 20150265580 | Brossard et al. | Sep 2015 | A1 |
| 20170319555 | Dingemanse et al. | Nov 2017 | A1 |
| 20170348287 | Clozel et al. | Dec 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 2521325 | Oct 2004 | CA |
| 0 627 406 | Dec 1994 | EP |
| 1 431 275 | Jun 2004 | EP |
| 1 431 284 | Jun 2004 | EP |
| T-2005-535679 | Nov 2005 | JP |
| WO 1998052944 | Nov 1998 | WO |
| WO 2002078766 | Oct 2002 | WO |
| WO 2002080902 | Oct 2002 | WO |
| WO 2002100148 | Dec 2002 | WO |
| WO 2003061567 | Jul 2003 | WO |
| WO 2003062252 | Jul 2003 | WO |
| WO 200401097 | Feb 2004 | WO |
| WO 2004010987 | Feb 2004 | WO |
| WO 2004028521 | Apr 2004 | WO |
| WO 2004103306 | Dec 2004 | WO |
| WO 2005054215 | Jun 2005 | WO |
| WO 2005123677 | Dec 2005 | WO |
| WO 2006010544 | Feb 2006 | WO |
| WO 2006041015 | Apr 2006 | WO |
| WO 2006058316 | Jun 2006 | WO |
| WO2006058316 | Jun 2006 | WO |
| WO 2006100631 | Sep 2006 | WO |
| WO 2006100633 | Sep 2006 | WO |
| WO 2006100635 | Sep 2006 | WO |
| WO 2006137019 | Dec 2006 | WO |
| WO 2007060626 | May 2007 | WO |
| WO 2007080542 | Jul 2007 | WO |
| WO 2007086001 | Aug 2007 | WO |
| WO 2008029306 | Mar 2008 | WO |
| WO 2008029370 | Mar 2008 | WO |
| WO 2008029371 | Mar 2008 | WO |
| WO 2008035239 | Mar 2008 | WO |
| WO 2008114157 | Sep 2008 | WO |
| WO 2009024905 | Feb 2009 | WO |
| WO 2009048993 | Apr 2009 | WO |
| WO 2009115954 | Sep 2009 | WO |
| WO 2010072703 | Jul 2010 | WO |
| WO 2010075239 | Jul 2010 | WO |
| Entry |
|---|
| Sanna et al, J. Biological Chemistry (2004), vol. 279 (14), pp. 13839-13848. (Year: 2004). |
| U.S. Appl. No. 14/308,598, filed Jun. 18, 2014, Brossard et al. |
| U.S. Appl. No. 14/322,801, filed Jul. 2, 2014, Brossard et al. |
| “Actelion's Orally Active Selective S1P1 Receptor Agonist to be Jointly Developed/Promoted with Roche in Autoimmune Disorders and Transplantation; Deal Potentially Worth Well Over US$630 Million to Actelion”, http://www.mskreport.com/print.cfm?articleID=827. Jul. 20, 2006. |
| Brinkmann, V. “Sphingosine 1-Phosphate Receptors in Health and Disease: Mechanistic Insights from Gene Deletion Studies and Reverse Pharmacology”, Pharmacol. Ther. (2007), vol. 115, pp. 84-105, (doi:10.1016/j.pharmathera.2007.04.006). |
| Bunemann, M., et al., “Activation of Muscarinic K+Current in Guinea-pig Atrial Myocytes by Sphingosine-1-phosphate”, Journal of Physiology, vol. 489, pp. 701-707, (1995). |
| Davidov, T., et al., “Chronic Nitric Oxide Synthase Blockade Desensitizes the Heart to the Negative Metabolic Effects of Nitric Oxide”, Life Sciences, Pergamon Press, Oxford, GB, vol. 79, pp. 1674-1680, (2006). |
| Frolkis, V.V., “The Role of ‘Invertors’ (Intracellular Activators) in Age-related Changes in Cell Response to Hormones”, Experimental Gerontology, vol. 30, pp. 401-414, (1995). |
| Fujishiro, J., et al., “Use of Sphingosine-1-Phosphate 1 Receptor Agonist, KRP-203, in Combination with a Subtherapeutic Dose of Cyclosporine A for Rat Renal Transplantation”, Transplantation, vol. 82(6), pp. 804-812, (2006). |
| Gould, P.L., “Salt Selection for Basic Drugs”, International Journal of Pharmaceutics, vol. 33, pp. 201-217, (1986). |
| Guo, J., et al., “Effects of Sphingosine 1-phosphate on Pacemaker Activity in Rabbit Sino-atrial Node Cells”, Pflugers Arch, vol. 438, pp. 642-648, (1999). |
| Hale, J., et al., “Selecting Against S1P3 Enhances the Acute Cardiovascular Tolerability of 3-(N-benzyl)aminopropylphosphonic Acid S1P Receptor Agonists”, Bioorganic & Medicinal Chemistry Letters, vol. 14(13), pp. 3501-3505, (2004). |
| Himmel, H., et al., “Evidence for Edg-3 Receptor-Mediated Activation of IK.Ach by Sphingosine-1-Phosphate in Human Atrial Cardiomyocytes”, Molecular Pharmacology, vol. 58, pp. 449-454, (2000). |
| Huwiler, A., et al., “New Players on the Center Stage: Sphingosine 1-Phosphate and its Receptors as Drug Targets”, Biochemical Pharmacology, Pergamon Press, Oxford, GB, vol. 75, pp. 1893-1900, (2008). |
| Kappos, L., et al., “Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis”, The New England Journal of Medicine, vol. 355(11), pp. 1124-1140, (2006). |
| Keller et al., “Immunomodulator FTY720 Induces Myofibroblast Differentiation via the Lysophospholipid Receptor S1P3 and Smad3 Signaling”, The American Journal of Pathology, vol. 170, No. 1, pp. 281-292 (2007). |
| Kovarik, J.M., et al., “A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod”, Journal of Clinical Pharmacology, vol. 48, No. 3, pp. 303-310, (2008). |
| Koyrakh, L., et al., “The Heart Rate Decrease Caused by Acute FTY720 Administration is Mediated by the G Protein-Gated Potassium Channel IKACh”, American Journal of Transplantation, vol. 5, pp. 529-536, (2005). |
| Ochi, R., et al., “Sphingosine-1-Phosphate Effects on Guinea Pig Atrial Myocytes: Alterations in Action Potentials and K+Currents”, Cardiovascular Research, vol. 70, pp. 88-96, (2006). |
| Peters, S., et al., “Sphingosine-1-Phosphate Signaling in the Cardiovascular System”, Current Opinion in Pharmacology, vol. 7(2), pp. 186-192, (2007). |
| Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]. |
| Sanna, M.G., et al., “Sphingosine 1-Phosphate (S1P) Receptor Subtypes SIP1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate”, The Journal of Biological Chemistry, vol. 279(14), pp. 13839-13848, (2004). |
| Schmouder et al., “FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects” Journal of Clinical Pharmacology, vol. 46, pp. 895-904 (2006). |
| “Clinical Trial” definition, Wikipedia.com, 17 pages. |
| “ICH Topic E 8 General Considerations for Clinical Trials”, European Medicines Agency, Mar. 1998, 14 pages. |
| Tozer et al., “Introduction to Pharmacokinetics and Pharmacodynamics—The Quantative Basis of Drug Therapy”, Lippincott Williams & Wilkins, Chapter 12, p. 257, (2006). |
| Aki, F.T., et al., “FTY720: A new kid on the block for transplant immunosuppression,” Expert Opin. Biol. Ther., 3(4): 665-681 (2003). |
| Birkett, D.J., “Pharmacokinetics made easy 11 Designing dose regimens,” Aust. Prescr., 19: 76-78 (1996). |
| Budde, K., et al., “First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients,” J. Am. Soc. Nephrol., 13: 1073-1083 (2002). |
| Brinkmann, V., et al., “The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors,” The Journal of Biological Chemistry, 277(24): 21453-21457 (2002). |
| Cook, C., et al., “Dosage Regimens and Dose-Response,” Encyclopedia of Pharmaceutical Technology, 3rd Edition, 1012-1022, (2007). |
| Cutler, N., et al., “Safety and Tolerability of Metrifonate in Patients with Alzheimer's Disease: Results of a Maximum Tolerated Dose Study,” Life Sciences, 62(16): 1433-1441 (1998). |
| Ettmayer, P., et al., “Lessons Learned from Marketed and Investigational Prodrugs,” Journal of Medicinal Chemistry, 47(10): 2392-2404 (2004). |
| Fujino, M., et al., “Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment,” The Journal of Pharmacology and Experimental Therapeutics, 305(1): 70-77 (2003). |
| Galinsky, R.E., et al., “Basic Pharmacokinetics and Pharmacodynamics,” The Science and Practice of Pharmacy, 1171 (2006). |
| Gilenya, EPAR Summary for the Public, European Medicines Agency, EMA/818399/2017, retrieved from the Internet Sep. 27, 2018, URL: <https://www.ema.europa.eu/documents/overview/gilenya-epar-summary-public_en.pdf>. |
| Kahan, B.D., “FTY720: A New Dimension in Transplantation,” Transplantation Proceedings, 33: 3081-3083 (2001). |
| Kahan, B.D., et al., “Pharmacodynamics, Pharmacokinetics, and Safety of Multiple Doses of FTY720 in Stable Renal Transplant Patients: A Multicenter, Randomized, Placebo-Controlled, Phase I Study,” Transplantation, 76(7): 1079-1084 (2003). |
| Kovarik, J., et al., “Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects,” J. Clin. Pharmacology, 44: 532-537 (2004). |
| Mikhailov, I.B., “Osnovi ratsionalnoi farmakotcrapii,” (Theory of rational pharmacotherapy), Tutorial on Clinical Pharmacotherapy for Students of Pediatric and Medical Departments of Institutions of Higher Education, St. Petersburg, p. 32 (1999) (Abstract). |
| Ogilvie, R., “An Introduction to Pharmacokinetics,” J. Chron. Dis., 36: 121-127 (1983). |
| Okoto, A.N. Lechenie automimunnogo tireoditida (Treatment of Autoimmune thyroiditis), Vitebsk, (1998). |
| Quesniaux, V., et al., “A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons,” Transplant Immunology, 7: 149-157 (1999). |
| Record, K.E., et al., “Oral Phenytoin Loading in Adults: Rapid Achievement of Therapeutic Plasma Levels,” Annals of Neurology, 5: 268-270 (1979). |
| Schmouder, R., et al., “Oral fingolimod (FTY720), 0.5 or 1.25 mg for 14 days has no effect on cardiac function,” World Congress Treatment and Research on Multiple Sclerosis, 14: S177 (2008). (Abstract). |
| Skerjanec, A., et al., “Systemic exposure and preliminary efficacy of FTY720 in de novo renal transplant recipients,” Am. J. Transplant., 2(Suppl. 3): 964 (Abstract) (2002). |
| Stella, V., “Prodrugs as therapeutics,” Expert Opinion on Therapeutic Patents, 14(3): 277-280 (2004). |
| Testa, B., “Prodrug research: futile or fertile?” Biochemical Pharmacology, 68: 2097-2106 (2004). |
| Vyshkovki, G.L., Index of Pharmaceuticals, Annual Index 5, 2003, OOO “RLS-2003” p. 1016. |
| Webb, M., et al., “Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice,” Journal of Neuroimmunology, 153: 108-121 (2004). |
| Wolff, Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., 1: 975-977 (1994). |
| Number | Date | Country | |
|---|---|---|---|
| 20140316140 A1 | Oct 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12922777 | US | |
| Child | 14322722 | US |
